Latest news
-
UK approves 1 mg dose of ALK’s EURneffy adrenaline nasal spray for children aged 4 and up
According ALK, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved use of a 1 mg dose of EURneffy adrenaline nasal spray for the treatment of anaphylaxis in children aged 4 and older who… [Read more . . .]
-
RDD 2026 in review
RDD 2026 once again gathered inhaled and nasal drug experts in Scottsdale, AZ, USA for 4 days of presentations, workshops, posters, and exhibitions focused on emerging technology, with more than 400 people participating. The conference… [Read more . . .]
-
Lupin partners with ERN for launch Luforbec beclometasone / formoterol MDI in Spain
Lupin Limited announced that it has partnered with Laboratorios ERN for the launch of Lupin’s Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD in Spain. Luforbec, a generic version of Chiesi’s… [Read more . . .]
-
MannKind initiates Phase 2 INFLO-2 trial of MNKD-201 nintedanib DPI in patients with IPF
MannKind Corporation announced the initiation of the Phase 2 INFLO-2 trial of its MNKD-201 nintedanib DPI in patients with idiopathic pulmonary fibrosis. The 12-week INFLO-2 study is expected to enroll approximately 210 IPF patients who… [Read more . . .]
-
SoftOx Solutions initiates Phase 1 SIS-02 trial of SIS hypochlorous acid inhalation solution
SoftOx Solutions announced the initiation of its Phase 1 SIS-02 study of SIS hypochlorous acid inhalation solution in healthy volunteers as part of a European Defense Fund-supported effort to develop the inhalation solution as a… [Read more . . .]
Other recent news
-
Scienture announces new US patent covering Rezenopy naloxone nasal spray
-
Nebu-Flow gets £2 million Scottish Enterprise grant for continued development of its nebulizer technology
-
FDA approves MannKind’s sBLA for pediatric use of Afrezza insulin DPI
-
Kvvit acquires rights to Merz’s Inbrija levodopa DPI in mainland China, Hong Kong, and Macao
-
Inhaled SSO developer Rage Bio rebrands as Atisama Therapeutics
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
